Thyroid gland papillary carcinoma
MONDO:0005075A differentiated adenocarcinoma arising from the follicular cells of the thyroid gland. Radiation exposure is a risk factor and it is the most common malignant thyroid lesion, comprising 75% to 80% of all thyroid cancers in iodine sufficient countries. Diagnostic procedures include thyroid ultrasound and fine needle biopsy. Microscopically, the diagnosis is based on the distinct characteristics of the malignant cells, which include enlargement, oval shape, elongation, and overlapping of the nuclei. The nuclei also display clearing or have a ground glass appearance.
Also known as: papillary cancer of the thyroid, papillary cancer of the thyroid gland, papillary cancer of thyroid, papillary cancer of thyroid gland, papillary carcinoma of the thyroid, papillary carcinoma of the thyroid gland, papillary carcinoma of thyroid, papillary carcinoma of thyroid gland
2814 clinical trials for this condition and its sub-types, 59 tagged with Thyroid gland papillary carcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Thyroid gland papillary carcinoma
-
Thyroid cancer, nonmedullary, 1 1 trial
-
Immunotherapy combo tested for tough thyroid cancers
Disease control Stopped earlyThis phase II trial tested two immunotherapy drugs, durvalumab and tremelimumab, in 79 patients with advanced thyroid cancer that had progressed despite treatment. The goal was to see if the combination could slow or stop cancer growth. The study was terminated early, so the full…
Phase 2 • Sponsor: Grupo Espanol de Tumores Neuroendocrinos • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug targets genetic weakness in tough cancers
Disease control Stopped earlyThis phase 2 trial tested the drug tovorafenib (DAY101) in 23 people aged 12 and older with recurrent or progressive solid tumors that have specific genetic changes in the MAPK pathway. The goal was to see how many patients' tumors shrank or disappeared. The study was terminated …
Phase 2 • Sponsor: Day One Biopharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC